(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Deciphera Pharmaceuticals, LLC
Eastern Cooperative Oncology Group
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Northwestern University
Blueprint Medicines Corporation
Wake Forest University Health Sciences
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Stanford University
Novartis
Wake Forest University Health Sciences
Children's Oncology Group
Wake Forest University Health Sciences
Fred Hutchinson Cancer Center
Wake Forest University Health Sciences
Vanderbilt University Medical Center
Mayo Clinic
Alliance for Clinical Trials in Oncology
Adelphi Values LLC
Novartis
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Asan Medical Center
Vanderbilt-Ingram Cancer Center
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
Mayo Clinic